Investigation of in vitro release kinetics of carbamazepine from Eudragit® RS PO and RL PO matrix tablets

Tropical Journal of Pharmaceutical Research

Volumn 8, Issue 2, 2009, Pages 145-152

  Apu, Apurba Sarker ^a   Pathan, Atiqul Haque ^a   Shrestha, Dilasha ^b   Kibria, Golam ^b   Jalil, Reza Ul ^b  

^a EAST WEST UNIVERSITY   (Bangladesh)

^b UNIVERSITY OF DHAKA   (Bangladesh)

Author keywords

Carbamazepine; Eudragit RL PO; Eudragit RS PO; Hardness; Matrix tablet; Release kinetics

Indexed keywords

CARBAMAZEPINE; EUDRAGIT; EUDRAGIT RS;

ARTICLE; CONTROLLED STUDY; DRUG RELEASE; MATRIX TABLET; TABLET HARDNESS;

EID: 69249090555     PISSN: 15965996     EISSN: 15969827     Source Type: Journal    
DOI: 10.4314/tjpr.v8i2.44523     Document Type: Article

References (22)

1. Alex A. Absorption and Drug Development. Hoboken, New Jersey, USA, John Wiley & Sons, Inc., 2003, pp 20-21.
2. Nair R, Gonen S, Hoag SW. Influence of polyethylene glycol and povidone on the polymorphic transformation and solubility of carbamazepine. Int J Pharm, 2002; 240: 11-22. (Pubitemid 34607698)
3. Reynolds JEF. Martindale, The Extra Pharmacopoeia. London, The Royal Pharmaceutical Society of Great Britain, 1993, pp 295.
4. Löbenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system; new scientific approaches to international regulatory standards. Eur J Pharm Biopharm, 2000; 50: 3-12. (Pubitemid 30326685)
5. Rinaki E, Valsami G, Macheras P. Quantitative biopharmaceutics classification system: The central role of dose/solubility ratio. Pharm Res, 2003; 20: 1917-1925. (Pubitemid 38005521)
6. Moneghini M, Voinovich D, Perissutti B, Princivalle F. Action of carriers on carbamazepine dissolution. Pharm Dev Technol, 2002; 7:289-296.
7. Bertilsson L. Clinical pharmacokinetics of carbamazepine. Clin Pharmacokinet, 1978; 3: 128-143.
8. Sivenius J, Heinonen E, Lehto H, Jaarvensivu P, Anttila M, Ylinen A, Riekkinen P. Reduction of Dosing Frequency of Carbamazepine with a Slow Release Preparation. Epilepsy Res, 1988; 2: 32-36. (Pubitemid 18008551)
9. Reza MS, Quadir MA, Haider SS. Comparative evaluation of plastic, hydrophobic and hydrophilic polymers as matrices for controlledrelease drug delivery. J Pharm Pharmaceut Sci, 2003; 6: 282-291.
10. Mehta KA, Kislaloglu MS, Phuapradit W, Malick AW, Shah NH. Release performance of a poorly soluble drug from a novel Eudragit-based multiunite erosion matrix. Int J Pharm, 2001; 213: 7-12. (Pubitemid 32119457)
11. Kibbe AH (ed.). Handbook of pharmaceutical excipients. Washington, D.C., USA, American Pharmaceutical Association, 2000, pp 401-406.
12. Harland R, Dubernet C, Benoit JP, Peppas N. A model of dissolution-controlled, diffusional drug release from non-swellable polymeric microspheres. J Control Rel, 1988; 7: 207-215. (Pubitemid 18224727)
13. Higuchi T. Mechanism of sustained action medication: Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci, 1963; 52: 1145-1149.
14. Hadjiioannou TP, Christian GD, Koupparis MA, Macheras PE. Quantitative Calculations in Pharmaceutical Practice and Research, New York, VCH Publishers Inc., 1993, pp 345-348.
15. Ritger PL, Peppas NA. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J Control Rel, 1987; 5: 37-42.
16. Donglu S. Biomedical Devices and Their Applications. Beijing, China, Springer, 2004, pp 1-31.
17. Capan Y. Influence of technological factors on formulation of sustained release tablets. Drug Dev Ind Pharm, 1965; 15: 927-956.
18. Stamm A, Tritsch JC. Some considerations on the liberation of drugs from inert matrices. Drug Dev Ind Pharm, 1986; 12: 2337-2353 (Pubitemid 17178877)
19. Hosseinali T, Seyed AM, Tina BG. Preparation of Sustained-Release Matrix Tablets of Aspirin with Ethylcellulose, Eudragit RS100 and Eudragit S100 and Studying the Release Profiles and their Sensitivity to Tablet Hardness. Iran J Pharm Res, 2003; 2: 201-206.
20. Paulo C, José MSL. Modeling and comparison of dissolution profiles. Eur J Pharm Sci, 2001; 13:123-133.
21. The United States Pharmacopoeia XXVII, Rockville, USA, The US Pharmacopoeial Convention, Inc., 2003, p 324.
22. Katdare A, Chaubal MV. Excipient Development for Pharmaceutical, Biotechnology, and Drug Delivery Systems. New York London, Informa Healthcare, 2006, pp 187-188.